Log on / register
Feedback | Support | My details
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J
Arthritis Res Ther 2005, 7:R439-44
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Sieper J, Rudwaleit M
Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv61-4
[PubMed Central] [PubMed] [Related articles]

2.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ
Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv2-14
[PubMed Central] [PubMed] [Related articles]

3.
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, ASAS Working Group
Ann Rheum Dis 2006 Mar, 65:316-20
[PubMed Central] [PubMed] [Related articles]

4.
ASAS/EULAR recommendations for the management of ankylosing spondylitis.
Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J, 'ASsessment in AS' international working group , European League Against Rheumatism
Ann Rheum Dis 2006 Apr, 65:442-52
[PubMed Central] [PubMed] [Related articles]

5.
TNFalpha blockade in human diseases: an overview of efficacy and safety.
Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR
Clin Immunol 2008 Jan, 126:13-30
[PubMed Central] [PubMed] [Related articles]


This article is also cited by 2 articles in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]

© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.